Equities research analysts predict that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will announce earnings of ($0.09) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for ZIOPHARM Oncology’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.07). ZIOPHARM Oncology posted earnings of ($0.15) per share during the same quarter last year, which indicates a positive year over year growth rate of 40%. The business is scheduled to announce its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.32) per share for the current fiscal year, with EPS estimates ranging from ($0.35) to ($0.26). For the next year, analysts forecast that the company will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03.

ZIOP has been the subject of several recent analyst reports. Zacks Investment Research cut ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. BidaskClub lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Saturday, December 22nd. Laidlaw initiated coverage on ZIOPHARM Oncology in a report on Monday, April 1st. They set a “buy” rating and a $7.50 target price on the stock. Finally, Lake Street Capital initiated coverage on ZIOPHARM Oncology in a report on Thursday, April 4th. They set a “buy” rating and a $7.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. ZIOPHARM Oncology currently has an average rating of “Buy” and a consensus target price of $5.85.

Shares of ZIOPHARM Oncology stock traded up $0.02 during midday trading on Wednesday, hitting $4.22. The company’s stock had a trading volume of 912,156 shares, compared to its average volume of 1,713,581. The stock has a market cap of $701.11 million, a PE ratio of -8.79 and a beta of 2.63. ZIOPHARM Oncology has a 1-year low of $1.56 and a 1-year high of $5.00.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Amalgamated Bank bought a new position in ZIOPHARM Oncology during the fourth quarter valued at about $37,000. Allred Capital Management LLC acquired a new stake in ZIOPHARM Oncology during the fourth quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new stake in ZIOPHARM Oncology during the fourth quarter valued at approximately $46,000. Legal & General Group Plc boosted its holdings in ZIOPHARM Oncology by 30.6% during the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 6,054 shares in the last quarter. Finally, Gamble Jones Investment Counsel acquired a new stake in ZIOPHARM Oncology during the fourth quarter valued at approximately $56,000. Institutional investors own 38.01% of the company’s stock.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Recommended Story: What factors cause inflation to rise?

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.